Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aptose Bioscienc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aptose Bioscienc's regulatory disclosures and financial reporting.
Aptose Biosciences Inc. filed its Q3 2025 report, highlighting ongoing development of tuspetinib while facing significant financial strain. The company reported a net loss of $5.1 million for the quarter and $17.7 million for the nine months. Cash, cash equivalents and restricted cash were $1.6 million as of September 30, 2025, with cash used in operations of $16.1 million year‑to‑date. Management states that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
To fund operations, Aptose relied on related‑party facilities with Hanmi: an $8.5 million facility fully drawn and an additional up to $11.9 million facility, of which $4.2 million was advanced by October 27, 2025. Loan payable to related party rose to $18.7 million. Shareholders’ deficit widened to $(19.5) million. The company effected a 1‑for‑30 reverse stock split on February 26, 2025 and used an ATM to raise $1.0 million gross. 2,552,429 common shares were outstanding as of November 7, 2025.
Aptose Biosciences Inc. furnished a press release under Item 7.01 (Regulation FD) via a Form 8-K. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
Consistent with General Instruction B.2, the Item 7.01 information is deemed furnished, not filed, and is not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated by specific reference.
FAQ
What is the current stock price of Aptose Bioscienc (APTOF)?
What is the market cap of Aptose Bioscienc (APTOF)?
